Eastgate Biotech (ETBI) Stock Price, News & Analysis

Company Overview

Eastgate Biotech, Inc. is a developmental-stage biotechnology company focused on the research and development of advanced lipid nanoparticle (LNP) drug delivery systems. The company’s proprietary platform is designed to facilitate the targeted transport of nucleic acid therapies, including mRNA and siRNA, to specific tissues in order to maximize therapeutic efficacy and minimize off-target effects. By harnessing the versatility of its LNP technology, Eastgate Biotech aims to enable the next generation of precision medicines for a variety of genetic and degenerative conditions.

Leveraging its LNP platform, Eastgate Biotech is assembling a pipeline of preclinical therapeutic candidates, with particular emphasis on ocular and neuromuscular applications. Through optimization of particle composition and surface characteristics, the company seeks to overcome traditional delivery barriers and advance treatments for diseases such as age-related macular degeneration and inherited muscular dystrophies. Eastgate’s development strategy includes collaborative research efforts with academic institutions and contract development organizations to enhance its technical capabilities and accelerate preclinical progress.

Headquartered in the United States, Eastgate Biotech operates as a publicly traded entity on the OTC Markets under the symbol ETBI. As a development-stage enterprise, the company currently does not have approved commercial products and is directing its resources toward advancing lead programs through preclinical validation. Eastgate continues to explore strategic partnerships, licensing arrangements and funding opportunities to support the transition of its novel therapies into clinical development.

Key Stats

• Today's Range: $0.0010 to $0.0010
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0045
• Volume: N/A
• Average Volume: 160,850 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ETBI Stock Analysis - Frequently Asked Questions

How have ETBI shares performed this year?

Eastgate Biotech's stock was trading at $0.0030 at the beginning of the year. Since then, ETBI shares have decreased by 66.7% and is now trading at $0.0010.

How do I buy shares of Eastgate Biotech?

Shares of ETBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eastgate Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eastgate Biotech investors own include Delcath Systems (DCTHD), OPKO Health (OPK), Ovintiv (OVV), Avino Silver & Gold Mines (ASM), CVS Health (CVS) and

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Trading
• Current Symbol: OTCMKTS:ETBI
• Previous Symbol: OTCMKTS:ESAQ
• CIK: 1099574
• Web: www.eastgatebiotech.com
• Phone: 647-692-0652
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A